Last reviewed · How we verify
Cardiovascular Polypill
A fixed-dose combination pill that combines multiple cardiovascular agents to reduce the risk of heart disease and stroke through complementary mechanisms including blood pressure lowering, lipid reduction, and antiplatelet effects.
A fixed-dose combination pill that combines multiple cardiovascular agents to reduce the risk of heart disease and stroke through complementary mechanisms including blood pressure lowering, lipid reduction, and antiplatelet effects. Used for Cardiovascular disease prevention and secondary prevention in high-risk patients.
At a glance
| Generic name | Cardiovascular Polypill |
|---|---|
| Also known as | Polypill |
| Sponsor | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III |
| Drug class | Fixed-dose combination / Polypill |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The polypill integrates several established cardiovascular drugs into a single tablet to improve medication adherence and provide synergistic cardioprotection. By combining agents that work through different pathways—such as antihypertensives, statins, and antiplatelet drugs—it aims to reduce overall cardiovascular event risk more effectively than individual medications while simplifying the treatment regimen.
Approved indications
- Cardiovascular disease prevention and secondary prevention in high-risk patients
Common side effects
- Hypotension
- Gastrointestinal disturbances
- Muscle pain or myalgia
- Bleeding risk
Key clinical trials
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- Secondary Prevention of Cardiovascular Disease in the Elderly Trial (PHASE3)
- Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial (PHASE3)
- Single Pill to Avert Cardiovascular Events (PHASE3)
- Prevention of Cardiovascular Disease With Polypill Among Pars Cohort Participants (PHASE3)
- A Polypill for Secondary Prevention of Ischemic Heart Disease (PHASE3)
- Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables. (PHASE3)
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |